Citigroup
CYCN icon

Citigroup’s Cyclerion Therapeutics CYCN Stock Holding History

Citigroup’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137 Sell
89
-8,115
-99% -$11.5K ﹤0.01% 5596
2025
Q4 		$10.4K Buy
+8,204
New +$14.6K ﹤0.01% 5041
2021
Q2 		– Sell
-73
Closed -$4K – 6168
2021
Q1 		$4K Sell
73
-141
-66% -$10.6K ﹤0.01% 5934
2020
Q4 		$13K Buy
214
+161
+304% +$11K ﹤0.01% 6856
2020
Q3 		$6K Sell
53
-106
-67% -$12.1K ﹤0.01% 6890
2020
Q2 		$19K Sell
159
-179
-53% -$15K ﹤0.01% 6646
2020
Q1 		$18K Sell
338
-87
-20% -$6.21K ﹤0.01% 6749
2019
Q4 		$23K Buy
425
+137
+48% +$12.8K ﹤0.01% 6865
2019
Q3 		$69K Sell
288
-24
-8% -$5.18K ﹤0.01% 5919
2019
Q2 		$71K Buy
+312
New +$88.3K ﹤0.01% 6162

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's CYCN Position: Q1 2026 in Review

Citigroup reduced its Cyclerion Therapeutics (CYCN) stake by 99% in Q1 2026, selling an estimated $11.5K and leaving 89 shares worth $137. The position accounts for ﹤0.01% of the portfolio, ranked #5596.

Citigroup first reported a position in CYCN in Q2 2019 and has held it in 10 quarters since. The position peaked at $71K in Q2 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Citigroup held 89 shares of Cyclerion Therapeutics worth $137 as of Q1 2026.
  • Citigroup sold 8,115 Cyclerion Therapeutics shares in Q1 2026, an estimated $11.5K.
  • Cyclerion Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5596 holding.
  • Citigroup first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 10 quarters since.
  • Citigroup's Cyclerion Therapeutics position peaked at $71K in Q2 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.